Working under the exceptions rule to adequate and well controlled trials is a delicate matter because all rests on final “approval” of BLA that is the final validation of SAP, ECAs and endpoint changes as necessary and adequate. When you understand this then you understand the points of attack. Best wishes.
Market Data 
Markets 
AI
